The Jackson Laboratory, a nonprofit biomedical research organization, has forged a strategic partnership with AbTherx, a biotechnology innovator, to advance antibody discovery and expedite the development of vital new therapies.

Metaphore Biotechnologies, in conjunction with Flagship Pioneering, has announced a significant research collaboration with Novo Nordisk aimed at developing innovative therapeutics for managing obesity.

Neurocrine Biosciences, Inc., has announced the initiation of its Phase 1 clinical trial to evaluate NBI-1076986, a novel compound targeting the M4 subtype-selective muscarinic acetylcholine receptor.

CEL-SCI Corporation has recently shared positive news from its discussion with the U.S. Food and Drug Administration regarding the approval pathway for its cancer immunotherapy, Multikine

Acepodia, a biotech firm in the clinical stages, has released initial findings from its Phase 1 dose escalation trial of ACE1831. This therapy, a fusion of an anti-CD20 antibody with allogeneic gamma delta T cells, is aimed at treating non-Hodgkin's lymphoma

Invivyd, Inc., a biopharmaceutical company specializing in combating severe viral infections, has disclosed its intention to seek emergency use authorization from the U.S. Food and Drug Administration for pemivibart.

TC BioPharm, a biotechnology company in the clinical stage, has recently announced its intention to acquire a privately-held biotechnology company. This company specializes in the development of Chimeric Antigen Receptor T-cell

AsclepiX Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in computational biology from Johns Hopkins to develop peptides for treating retinal diseases, has announced the completion

Gossamer Bio, Inc., a biopharmaceutical company focusing on the clinical development and commercialization of seralutinib for treating pulmonary arterial hypertension and pulmonary hypertension

Amolyt Pharma has received Fast Track designation from the FDA for its Phase 3 development targeting hypoparathyroidism. The Fast Track process expedites drug review for serious conditions with unmet medical needs.